Skip to main content
SpringerLink
Log in

Prävention viraler Infektionen

Bei immunsupprimierten Patienten mit soliden Tumoren und hämatologischen Neoplasien

  • Topic
  • Published:
best practice onkologie Aims and scope

Eine wesentliche Komplikation in der Betreuung von Patienten mit soliden Tumoren und hämatologischen Neoplasien sind opportunistische Infektionen. Im Vordergrund stehen dabei bakterielle Infektionen, die vor allem während febriler Neutropenie das Risiko für Morbidität und Letalität entscheidend prägen. Invasive Mykosen sind in der Behandlung solider Tumoren eine Seltenheit, stellen aber während Chemotherapie akuter Leukämien und nach allogener Stammzelltransplantation (SZT) eine klinisch relevante Herausforderung dar. Im Gegensatz dazu ist das Risiko für das Auftreten viraler Infektionen (jenseits saisonaler Atemwegsinfektionen) bei Patienten mit soliden Tumoren und hämatologischen Neoplasien außerhalb der allogenen SZT verhältnismäßig gering, gilt aber dennoch im klinischen Alltag als eine wichtige Komplikation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Angarone M (2011) Epidemiology and prevention of viral infections in patients with hematologic malignancies. Infect Disord Drug Targets 11:27–33

    Article  CAS  PubMed  Google Scholar 

  2. Kunisaki KM et al (2009) Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9:493–504

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sandherr M et al (2015) Antiviral prophylaxis in patients with solid tumours and haematological malignancies-update of the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Oncology (DGHO). Ann Hematol 94:1441–1450

    Article  Google Scholar 

  4. Hicks KL et al (2003) Common community respiratory viruses in patients with cancer: more than just „common colds“. Cancer 97:2576–2587

    Article  PubMed  Google Scholar 

  5. Huang YW et al (2012) Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol 5:359–370

    Article  PubMed  PubMed Central  Google Scholar 

  6. Engelhard D et al (2013) European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis 15:219–232

    Article  CAS  PubMed  Google Scholar 

  7. Evens AM et al (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170–1180

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. European Association For The Study Of The Liver. (2012) EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167–185

    Article  Google Scholar 

  9. Swaika A et al (2012) Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol 10:155–159

    Article  CAS  PubMed  Google Scholar 

  10. Weissinger F et al (2012) Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 91:1161–1174

    Article  PubMed  Google Scholar 

  11. Heine A et al (2013) Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122(23):3843–3844

    Article  CAS  PubMed  Google Scholar 

  12. Warkentin DI et al (2002) Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients. Ann Pharmacother 36:1525–1531

    Article  CAS  PubMed  Google Scholar 

  13. Ling WH et al (2013) Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer 108:1931–1935

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yeo W et al (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605–611

    Article  CAS  PubMed  Google Scholar 

  15. Reddy KR et al (2015) American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:215–219

    Article  Google Scholar 

  16. Liang R (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113:3147–3153

    Article  CAS  PubMed  Google Scholar 

  17. Li HC et al (2015) Hepatitis C virus: virology, diagnosis and treatment. World J Hepatol 7:1377–1389

    Article  Google Scholar 

  18. Kish MA (2001) Guide to development of practice guidelines. CID 32:851–854

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Weilheim, Deutschland

    M. Sandherr (Gemeinschaftspraxis für Hämatologie und Onkologie)

  2. Medizinische Klinik und Poliklinik III, Klinikum der Universität München, München, Deutschland

    C. Rieger

  3. Klinik für Hämatologie, Onkologie und Palliativmedizin, Klinikum Ernst von Bergmann, Potsdam, Deutschland

    G. Maschmeyer

  4. Röntgenstr. 4, 82362, Weilheim, Deutschland

    M. Sandherr (Gemeinschaftspraxis für Hämatologie und Onkologie)

Authors
  1. M. Sandherr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Rieger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Maschmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Sandherr.

Additional information

Einhaltung ethischer Richtlinien Interessenkonflikt

M. Sandherr, C. Rieger und G. Maschmeyer: Keine Angaben.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sandherr, M., Rieger, C. & Maschmeyer, G. Prävention viraler Infektionen. best practice onkologie 11, 17–23 (2016). https://doi.org/10.1007/s11654-016-0576-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-016-0576-3

Search

Navigation